• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    AbbVie Pens $5.6B Pact with RemeGen to join PD-1xVEGF race

    PRESS RELEASE

    Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data

    GLOBENEWSWIRE

    Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data

    GLOBENEWSWIRE

    Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN

    GLOBENEWSWIRE

    Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus

    GLOBENEWSWIRE

    Telitacicept Phase III Data In Sjögren`s Syndrome At 2025 ACR

    PR NEWSWIRE

    Vor Bio Presents Phase 3 Sjögren`s Disease Study Poster At ACR

    GLOBENEWSWIRE

    Vor Bio Presents 48-Week China Ph 3 Myasthenia Gravis Study

    GLOBENEWSWIRE

    RemeGen`s Telitacicept Result sets up IgAN Submission in China

    FIERCE PHARMA

    RemeGen Trades Asia Rights of VEGF/FGF Eye Drug for $180M

    FIERCE BIOTECH

    FDA Approves RemeGen`s RC148 for Phase II Clinical Trial in US

    PR NEWSWIRE

    RemeGen`s Telitacicept Approved for Generalized Myasthenia Gravis

    PR NEWSWIRE

    Pfizer partner touts HER2 ADC trial win in bladder cancer

    FIERCE PHARMA

    RemeGen’s Disitamab Vedotin Shows Promise In Ph2 Bladder Cancer

    PR NEWSWIRE

    RemeGen`s Marketing Application for Telitaccept Accepted in China

    PR NEWSWIRE

    RemeGen: ASCO 2024 Highlights Global Cancer Innovation

    PR NEWSWIRE

    RemeGen`s RC88 ADC Shows Proof-Of-Concept Phase 1/2 Results

    PR NEWSWIRE

    RemeGen`s Telitacicept Granted Fast Track Designation by FDA

    PR NEWSWIRE

    RemeGen Presents Presentation on Evaluation of Its Proprietary Disitamab Vedotin

    PR NEWSWIRE

    RemeGen Announces Continued Inclusion of Telitacicept in Reimbursement Drug List

    PR NEWSWIRE

    RemeGen Announces Publication of Results from Phase II for Disitamab Vedotin

    PR NEWSWIRE

    RemeGen to Present Telitacicept PIII Trial Results for Rheumatoid Arthritis

    PR NEWSWIRE

    RemeGen`s Telitacicept Shows Promise in PII Trial for Primary Sjogren`s Syndrome

    PR NEWSWIRE

    RemeGen & Innovent Collaborate on Trials to Evaluate Potential of RC88 and RC108

    PR NEWSWIRE

    Innovent & RemeGen Enter into Trial Collab Invesg Combination Therapy of TYVYT

    PR NEWSWIRE

    RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.